In this study, we identify an unexpected and previously unrecognized role for PI3Kδ in promoting stromal fibrosis in PDAC, expanding its known function beyond immune regulation. Through mechanistic and preclinical studies, we show that PI3Kδ controls the biosynthesis of LPA in cancer cells and stromal fibroblasts, establishing an immunometabolic axis that sustains both fibrosis and immune evasion in PDAC.
Strikingly, PI3Kδ inhibition alone was sufficient to suppress tumor growth, reduce fibrosis, restore antitumor immune responses, and prolong survival across multiple PDAC models. Dual inhibition of PI3Kδ and ATX produced additive effects on stromal remodeling and immune activation, significantly enhancing responsiveness to chemotherapy and PD-1 blockade. These findings position PI3Kδ as a central regulator of the PDAC tumor microenvironment and highlight its therapeutic targeting, alone or in combination, as a promising strategy to treat PDAC.









